中国医学创新2024，Vol.21Issue(18)：27-31,5.DOI:10.3969/j.issn.1674-4985.2024.18.007
卡瑞利珠单抗联合仑伐替尼一线治疗晚期HCC临床效果及安全性观察
Clinical Efficacy and Safety of Camrelizumab Combined with Lenvatinib in First-line Treatment of Advanced HCC
摘要
Abstract
Objective:To analyze the clinical efficacy and safety of Camrelizumab combined with Lenvatinib in the first-line treatment of advanced hepatocellular carcinoma(HCC).Method:A total of 80 patients with advanced HCC in Jiujiang NO.1 People's Hospital from January 2019 to January 2022 were taken as the study subjects,and they were divided into control group and study group according to the interval randomization method.The control group was treated with Lenvatinib,and the study group received Camrelizumab combined with Lenvatinib.Progression-free survival(PFS),overall survival(OS),objective response rate(ORR)and disease control rate(DCR),and liver function indicators[aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBIL)]before and after treatment,functional status score(KPS)of tumor patients and the occurrence of adverse reactions during treatment in two groups were compared.Result:The PFS and OS of the study group were longer than those of the control group(P<0.05).The ORR(75.00%)and DCR(92.50%)of the study group were higher than those(50.00%,75.00%)of the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in liver function indexes between the two groups before treatment(P>0.05).After 2 months of treatment,the levels of ALT,AST and TBIL in the two groups were significantly lower than those before treatment,and those in the study group were lower than those in the control group(P<0.05).There was no significant difference in KPS score between the two groups before treatment(P>0.05).After 2 months of treatment,the KPS scores of the two groups increased,and the KPS score of the study group was higher than that of the control group(P<0.05).The incidence of adverse reactions during treatment in the control group and the study group was 12.50%and 15.00%,respectively,the difference was not statistically significant(P>0.05).Conclusion:Camrelizumab combined with Lenvatinib in first-line treatment are effective and safe in HCC.关键词
卡瑞利珠单抗/仑伐替尼/晚期肝细胞癌/安全性Key words
Camrelizumab/Lenvatinib/Advanced hepatocellular carcinoma/Safety引用本文复制引用
汤蕾,左宏波,刘秋连,李言冰,夏云,王志,石鑫..卡瑞利珠单抗联合仑伐替尼一线治疗晚期HCC临床效果及安全性观察[J].中国医学创新,2024,21(18):27-31,5.基金项目
江西省卫生健康委科技计划项目(202211875) （202211875）
